7.35 USD
▲+0.01+0.14%
盘后 7.41 +0.82%
2026-11-19
市值
$634.88M
市盈率
—
EPS
-3.30
股息率
—
52 周区间
6.75 – 13.90
成交量
1.66M
Beta
0.53
目标价
31.62
52W 低 6.7552W 高 13.90
价格走势
公司简介
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional n...